

Creation of a Predefined Interatrial Communication with the Occlutech® Atrial Flow Regulator

Jacek Baranowski¹, Henrik Ahn^{1,2}, Joseph J. Vettukattil^{3,4}

¹ Heart Center, Linköping University Hospital, Linköping, Sweden

² Department of Medical and Health Sciences, Linköping University, Linköping, Sweden

³ Congenital Heart Center, Helen DeVos Children's Hospital of Spectrum Health, Grand Rapids, MI, USA

⁴ College of Human Medicine, Michigan State University, Grand Rapids, MI, USA

Background

- Permanent interatrial communication with a defined diameter is beneficial for palliation of congenital heart conditions with obstructive lesions, failing Fontan circulation, heart failure, and pulmonary hypertension.
- The predetermined atrial communication allows for shunting, maintaining adequate cardiac output.
- Although percutaneous stent implantation and balloon dilatation are well-established techniques to create an atrial communication, they often result in complications such as spontaneous closure of the fenestration, excessive desaturation, and stent embolization.
- The lack of a safe and effective interventional device for creating a sustainable atrial fenestration led to the development of the Occlutech® Atrial Flow Regulator (AFR) device (Figure 1).

Objective

- To evaluate the safety, and efficacy of the AFR device in a porcine model.

Methods

- Eight 2.5 month old piglets weighing 35-50 kg underwent AFR implantation.
- Hemodynamic changes, device position and patency were monitored using echocardiography and fluoroscopy for 3 months.
- Tissue reaction and histopathological changes were also studied.



Figure 1: Occlutech® Atrial Flow Regulator

Table 1. Pre- and post-implantation hemodynamics and fenestration patency at 3 months

Piglet	Device fenestration size (mm)	Pulmonary artery oxygen saturation (%)		Mean pulmonary artery pressure (mmHg)		Qp:Qs		Fenestration patency
		Pre-	Post-	Pre-	Post-	Pre-	Post-	
1	8	54.2	53.0	-	17	1:1	1.16:1	Patent
2	10	55.6	42.4	-	25	0.9:1	1.2:1	Excluded
3	8	61.3	63.1	-	10	0.88:1	1:1	Patent
4	6	66.4	63.4	-	18	1:1	1.08:1	Occluded
5	10	67.8	58.0	13	11	1:1	1:1	Patent
6	4	-	-	-	-	-	-	Excluded
7	4	68.5	62.9	19	15	0.9:1	1:1	Occluded
8	6	62.3	60.7	14	11	1.08:1	1.08:1	Patent




Figure 2: Explanted device (Animal 5) with complete fenestration patency despite full endothelialization viewed from the A) left atrium and B) right atrium.

Results

- Eight animals were included in the study. The AFR was successfully implanted in 6 pigs; 2 were excluded from the study (Table 1).
- Device patency was demonstrable on echocardiography at 1 day after implantation (n=6).
- At 1-month follow-up, 2 pigs had spontaneous closure of the fenestration, but device patency was maintained in the remaining 4 piglets throughout the study period.
- Postmortem examination demonstrated patent shunts (Figure 2) with neoendothelialization (n=4), and slight decrease in pulmonary artery oxygen saturation 61.4 ± 5.59 to 58.7 ± 4.33 mmHg, but was not found to be significantly different at follow-up (p=0.3568). There was no statistically significant difference in the Qp/Qs before and after implantation (p=0.1881).
- No tissue reaction was noted at the implantation site (n=6).

Conclusion

- The AFR device was found to be easy to deploy, safe, and effective in creating and maintaining a permanent atrial communication.

References

- Bhamra-Ariza P, Keogh AM, Muller DWM. Percutaneous interventional therapies for the treatment of patients with severe pulmonary hypertension. J Am Coll Cardiol 2014;63:611-618.
- Stümper O, Gewillig M, Vettukattil J, Budts W, Chessa M, Chaudhari M, Wright JG. Modified technique of stent fenestration of the atrial septum. Heart 2003;89:1227-1230.
- Sivaprakasam M, Kiesewetter C, Veldtman GR, Salmon AP, Vettukattil J. New technique for fenestration of the interatrial septum. J Interv Cardiol 2006;19:334-336.